<p>截至 2025 年 4 月 7 日，医疗保健行业的三只股票可能正在向那些将动量视为交易决策关键标准的投资者发出真正的警告。</p>
<p>相对强弱指数（RSI）是一种动量指标，它比较股票在价格上涨时的强度与价格下跌时的强度。与股票的价格走势相比，它可以让交易者更好地了解股票在短期内的表现。根据 Benzinga Pro，当 RSI 超过 70 时，通常认为该资产被超买。</p>
<p>以下是该行业最新的主要超买股票名单。</p>
<h3><strong>Alumis Inc ALMS</strong></h3>
<ul>
<li>在 3 月 25 日，Alumis, Inc 宣布与 Kaken Pharmaceuticals 达成合作和许可协议。根据该协议，Alumis 将许可 ESK-001，这是一种旨在治疗各种疾病中免疫失调的药物，授权 Kaken 在日本进行开发、生产和商业化，限于皮肤科应用。该公司的股票在过去一个月上涨了约 106%，52 周高点为 13.50 美元。</li>
<li><strong>RSI 值：</strong> 77.4</li>
<li><strong>ALMS 价格走势：</strong> Alumis 的股票在周五上涨了 17.7%，收于 10.05 美元。</li>
</ul>
<h3><strong>Chimerix Inc CMRX</strong></h3>
<ul>
<li>在 3 月 21 日，Chimerix 报告季度每股亏损 25 美分，超出分析师一致预期的 26 美分亏损。该公司报告季度销售额为 57,000 美元，低于分析师一致预期的 75,000 美元，差距为 24%。该公司的股票在过去六个月上涨了约 837%，52 周高点为 8.54 美元。</li>
<li><strong>RSI 值：</strong> 82.7</li>
<li><strong>CMRX 价格走势：</strong> Chimerix 的股票在周五收于 8.53 美元。</li>
</ul>
<h3><strong>Journey Medical Corp DERM</strong></h3>
<ul>
<li>在 4 月 1 日，Journey Medical Corporation 任命 Ramsey Alloush 为首席运营官。Journey Medical 的总裁兼首席执行官 Claude Maraoui 表示：“Ramsey 晋升为首席运营官反映了他卓越的领导能力以及他在我们公司增长中所发挥的关键作用。他对我们业务和行业的深刻理解使他能够推动我们的战略举措，专注于运营卓越和最大化股东价值。” 该公司的股票在过去一个月上涨了约 40%，52 周高点为 7.29 美元。</li>
<li><strong>RSI 值：</strong> 77.3</li>
<li><strong>DERM 价格走势：</strong> Journey Medical 的股票在周五上涨了 9.1%，收于 7.19 美元。</li>
</ul>
<p>了解更多关于 BZ Edge 排名的信息——点击查看该行业其他股票的评分以及它们的比较。</p>
<p><strong>接下来阅读：</strong></p>
<ul>
<li><strong>华尔街最准确的分析师对 3 只超过 4% 股息收益率的医疗保健股票的看法</strong></li>
</ul>
<p><em>图片来源于 Shutterstock</em></p>

DERM

CMRX

ALMS

<p>三只医疗保健股票，Alumis Inc (ALMS)、Chimerix Inc (CMRX) 和 Journey Medical Corp (DERM)，由于高相对强弱指数（RSI）值显示超买状态，正出现潜在下跌的迹象。Alumis 最近上涨了 106%，收盘价为 10.05 美元，RSI 为 77.4。Chimerix 报告了季度亏损，但在六个月内上涨了 837%，收盘价为 8.53 美元，RSI 为 82.7。Journey Medical 任命了一位新首席运营官，最近上涨了 40%，收盘价为 7.19 美元，RSI 为 77.3。投资者应保持谨慎，因为这些股票可能面临调整</p>

<p>As of April 7, 2025, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.</p>
<div class="lb-trans"><p>截至 2025 年 4 月 7 日，医疗保健行业的三只股票可能正在向那些将动量视为交易决策关键标准的投资者发出真正的警告。</p>
</div><p>The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to Benzinga Pro.</p>
<div class="lb-trans"><p>相对强弱指数（RSI）是一种动量指标，它比较股票在价格上涨时的强度与价格下跌时的强度。与股票的价格走势相比，它可以让交易者更好地了解股票在短期内的表现。根据 Benzinga Pro，当 RSI 超过 70 时，通常认为该资产被超买。</p>
</div><p>Here's the latest list of major overbought players in this sector.</p>
<div class="lb-trans"><p>以下是该行业最新的主要超买股票名单。</p>
</div><h3><strong>Alumis Inc ALMS</strong></h3>
<div class="lb-trans"><h3><strong>Alumis Inc ALMS</strong></h3>
</div><ul>
<li>On March 25, Alumis, Inc announced it entered into a collaboration and licensing agreement with Kaken Pharmaceuticals. Under the agreement, Alumis is licensing ESK-001, a drug aimed at treating immune dysregulation in various diseases, to Kaken for development, manufacturing and commercialization in Japan, limited to dermatologic applications.. The company's stock gained around 106% over the past month and has a 52-week high of $13.50.</li>
<li><strong>RSI Value:</strong> 77.4</li>
<li><strong>ALMS Price Action:</strong> Shares of Alumis gained 17.7% to close at $10.05 on Friday.</li>
</ul>
<div class="lb-trans"><ul>
<li>在 3 月 25 日，Alumis, Inc 宣布与 Kaken Pharmaceuticals 达成合作和许可协议。根据该协议，Alumis 将许可 ESK-001，这是一种旨在治疗各种疾病中免疫失调的药物，授权 Kaken 在日本进行开发、生产和商业化，限于皮肤科应用。该公司的股票在过去一个月上涨了约 106%，52 周高点为 13.50 美元。</li>
<li><strong>RSI 值：</strong> 77.4</li>
<li><strong>ALMS 价格走势：</strong> Alumis 的股票在周五上涨了 17.7%，收于 10.05 美元。</li>
</ul>
</div><h3><strong>Chimerix Inc CMRX</strong></h3>
<div class="lb-trans"><h3><strong>Chimerix Inc CMRX</strong></h3>
</div><ul>
<li>On March 21, Chimerix reported quarterly losses of 25 cents per share which beat the analyst consensus estimate of a loss of 26 cents per share. The company reported quarterly sales of $57.00 thousand which missed the analyst consensus estimate of $75.00 thousand by 24.00 percent. The company's stock gained around 837% over the past six months and has a 52-week high of $8.54.</li>
<li><strong>RSI Value:</strong> 82.7</li>
<li><strong>CMRX Price Action:</strong> Shares of Chimerix closed at $8.53 on Friday.</li>
</ul>
<div class="lb-trans"><ul>
<li>在 3 月 21 日，Chimerix 报告季度每股亏损 25 美分，超出分析师一致预期的 26 美分亏损。该公司报告季度销售额为 57,000 美元，低于分析师一致预期的 75,000 美元，差距为 24%。该公司的股票在过去六个月上涨了约 837%，52 周高点为 8.54 美元。</li>
<li><strong>RSI 值：</strong> 82.7</li>
<li><strong>CMRX 价格走势：</strong> Chimerix 的股票在周五收于 8.53 美元。</li>
</ul>
</div><h3><strong>Journey Medical Corp</strong> DERM</h3>
<div class="lb-trans"><h3><strong>Journey Medical Corp DERM</strong></h3>
</div><ul>
<li>On April 1, Journey Medical Corporation named Ramsey Alloush as Chief Operating Officer. Claude Maraoui, President and Chief Executive Officer of Journey Medical, said, “Ramsey’s promotion to COO reflects his exceptional leadership and the critical role he has played in our Company’s growth. His deep understanding of our business and the industry uniquely positions him to drive our strategic initiatives forward, focusing on operational excellence and maximizing shareholder value.” The company's stock gained around 40% over the past month and has a 52-week high of $7.29.</li>
<li><strong>RSI Value:</strong> 77.3</li>
<li><strong>DERM Price Action:</strong> Shares of Journey Medical gained 9.1% to close at $7.19 on Friday.</li>
</ul>
<div class="lb-trans"><ul>
<li>在 4 月 1 日，Journey Medical Corporation 任命 Ramsey Alloush 为首席运营官。Journey Medical 的总裁兼首席执行官 Claude Maraoui 表示：“Ramsey 晋升为首席运营官反映了他卓越的领导能力以及他在我们公司增长中所发挥的关键作用。他对我们业务和行业的深刻理解使他能够推动我们的战略举措，专注于运营卓越和最大化股东价值。” 该公司的股票在过去一个月上涨了约 40%，52 周高点为 7.29 美元。</li>
<li><strong>RSI 值：</strong> 77.3</li>
<li><strong>DERM 价格走势：</strong> Journey Medical 的股票在周五上涨了 9.1%，收于 7.19 美元。</li>
</ul>
</div><p>Learn more about BZ Edge Rankings—click to see scores for other stocks in the sector and see how they compare.</p>
<div class="lb-trans"><p>了解更多关于 BZ Edge 排名的信息——点击查看该行业其他股票的评分以及它们的比较。</p>
</div><p><strong>Read This Next:</strong></p>
<div class="lb-trans"><p><strong>接下来阅读：</strong></p>
</div><ul>
<li><strong>Wall Street’s Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 4% Dividend Yields</strong></li>
</ul>
<div class="lb-trans"><ul>
<li><strong>华尔街最准确的分析师对 3 只超过 4% 股息收益率的医疗保健股票的看法</strong></li>
</ul>
</div><p><em>Photo via Shutterstock</em></p>
<div class="lb-trans"><p><em>图片来源于 Shutterstock</em></p>
</div>

第二季度可能崩盘的三大医疗保健股票